Working... Menu
Trial record 27 of 430 for:    ifosfamide

Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00173862
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : July 25, 2007
Information provided by:
National Taiwan University Hospital

Brief Summary:
The purpose of this study is to evaluate the efficacy of Gemcitabine plus Ifosfamind as second line chemotherapy in advanced transitional cell carcinoma in terms of response rate and overall survival .

Condition or disease Intervention/treatment Phase
Transitional Cell Carcinoma Drug: Gemcitabine, Ifosfamide Phase 2

Detailed Description:

Cisplatin-based combination chemotherapy produces a response rate of 40-70% in TCC patients. However, only less than 10% of the patients can achieve long-term remission. Until now, there is no standard chemotherapy for cisplatin-failed TCC patients. Both gemcitabine and ifosfamide have been identified to have response rates of 20% or more in pretreated TCC patients. It is thus reasonable to combine these two active drugs as a second-line treatment for TCC.

Patients enrolled must have a pathologically proven urothelial transitional cell carcinoma (TCC) and must have exposed to one cisplatin-based combination chemotherapy for the advanced disease. GI regimen will be continued until maximal response.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced Transitional Cell Carcinoma
Study Start Date : May 2000
Actual Study Completion Date : June 2006

Arm Intervention/treatment
Experimental: A Drug: Gemcitabine, Ifosfamide

Primary Outcome Measures :
  1. Response rate [ Time Frame: 2000~2006 ]

Secondary Outcome Measures :
  1. Overall Survival, Safety [ Time Frame: 2000~2006 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed transitional cell carcinoma
  • Advanced / metastatic disease failed to prior chemotherapy (diagnostically confirmed disease progression during the treatment of last chemotherapy or within 6 months after the end of last chemotherapy)
  • Presence of at least one measurable disease which is defined as lesion that can be measured in at least 1 dimension as ³ 20 mm with conventional technique or ³ 10 mm with spiral CT scan
  • Performance status of ECOG 0, 1, 2
  • Age 20 years or older
  • Life expectancy more than 3 months
  • Adequate hematopoietic function as defined below:

    • WBC ³ 3,000/uL
    • Platelets ³ 75,000/Ul
  • Adequate organ function as defined below:

    • Total bilirubin £ 1.5 ´ ULN
    • ALT / AST£ 5 ´ ULN
    • Creatinine £ 1.5 mg/dL
  • Adequate serum electrolyte concentration:

    • 4 mmol/L<[K+] <5.3 mmol/L
    • 0.74 mmol/L<[Mg2+] <1.03 mmol/
    • 2.02 mmol/L<[Ca2+]<2.60 mmol/L
  • Result of ECG assessment: QTC < 460 msec
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Received chemotherapy, radiotherapy, surgery, or other investigational drug within 4weeks prior to entering the study
  • Receiving other concurrent palliative chemotherapy, radiotherapy, hormonal therapy, or other investigational drug except non-disease related conditions (e.g. insulin for diabetes) during study period
  • Presence of CNS metastasis
  • Previous or current malignancy with the exception of curatively treated non- melanoma skin cancer or cervical carcinoma in situ
  • Presence of serious concomitant illness which might be aggravated by study medication:

    1. Uncontrolled infection (active serious infections that are not controlled by antibiotics)
    2. Peripheral neuropathy grade 2 or higher (by NCI common toxicity criteria in sensory or motor neuropathy)
    3. Clinically significant arrhythmia (electrocardiogram QTc greater than 500 msec)
    4. Prior myocardial infarction or serious coronary arterial disease within the last 12 months
  • Mental status is not fit for clinical trial.
  • Women of child-bearing potential (pregnancy or breast feeding)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00173862

Layout table for location information
Department of Oncology , National Taiwan University Hospital
Taipei, Taiwan, 100
Sponsors and Collaborators
National Taiwan University Hospital
Layout table for investigator information
Principal Investigator: Chih-Hung Hsu, M.D., Ph.D. Department of Oncology , National Taiwan University Hospital
Study Chair: Ann-Lii Cheng, M.D., Ph.D. Department of Oncology, National Taiwan University Hospital

Layout table for additonal information Identifier: NCT00173862     History of Changes
Other Study ID Numbers: 155I1
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: July 25, 2007
Last Verified: June 2005

Keywords provided by National Taiwan University Hospital:
Combination, Chemotherapy,transitional cell carcinoma

Additional relevant MeSH terms:
Layout table for MeSH terms
Isophosphamide mustard
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Alkylating Agents